About VIP Partners
VIP Partners is a Financial Services company based in Altendorf (Switzerland). Early-stage venture capital is invested in US and Europe. It operates on a B2B model. Its focus areas include Investment Industry, Venture Capital Funds, Independent Funds and Conventional VCs.
Company details
VI Partners is based in Altendorf, Switzerland, with operations centered on early-stage venture capital. Investments are directed toward Life Sciences and IT sectors across the US and Europe. Portfolio holdings include companies like Activaero, Advanon, Altoida, and Amal Therapeutics. Focus is maintained on supporting emerging technologies and healthcare innovations through equity funding.
- Headquarters Altendorf, Switzerland
- SectorsFinancial Services
- Website vipartners.ch
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vip Partners
Complete news archive for VIP Partners
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VIP Partners
VIP Partners is headquartered in Altendorf, Switzerland. It is registered at Altendorf, Schwyz, Switzerland.
VI Partners is based in Altendorf, Switzerland, with operations centered on early-stage venture capital. Investments are directed toward Life Sciences and IT sectors across the US and Europe. Portfolio holdings include companies like Activaero, Advanon, Altoida, and Amal Therapeutics. Focus is maintained on supporting emerging technologies and healthcare innovations through equity funding.